TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript
Summarize this article with:
SA Transcripts157.37K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies December 15, 2025 2:00 PM EST Company Participants Mary Szela - CEO, President & DirectorRichard Marshall - Medical DirectorRichard Marshak - Chief Commercial OfficerAndrea Marasso - Vice President of Marketing Conference Call Participants Juan CamachoNelson Cox - Lake Street Capital Markets, LLC, Research DivisionWilliam Plovanic - Canaccord Genuity Corp., Research DivisionCarl Byrnes - Northland Capital Markets, Research Division Presentation Operator Good afternoon, and welcome to the TriSalus Life Sciences Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the TriSalus website following the conclusion of the event. I'd now like to turn the call over to Mary Szela, Chief Executive Officer and President at TriSalus Life Sciences. Please go ahead, Mary. Mary SzelaCEO, President & Director Thank you, and thank you all for joining today. I'm really excited to kick off this session with Dr. Juan Camacho, who has innovated a very innovative new approach for Thyroid Artery Embolization. And before we dive into that information, let me do a quick overview of TriSalus. So if you can advance the slide to just a brief overview slide, I think it's in 2. And TriSalus is a company that is focused on improving outcomes for patients with solid tumors in the liver, the pancreas, and you can go to the next slide, Dr. Camacho, keep going to the next one, this one, TriSalus At a Glance. And so our mission is to improve outcomes in patients who have tumors in the liver, in the pancreas and other solid tumors. And we do that through a platform technology that can actually modulate pressure and flow to deliver more therapy into the tumor and prevent any off-target delivery.